#Japan #Tokyo #Hitachi #HVCT RM #Cellseed

Overview of the New Platform

In a significant move towards revolutionizing regenerative medicine, Hitachi Ltd. has launched an innovative integrated management platform known as the "Hitachi Value Chain Traceability Service for Regenerative Medicine" (HVCT RM). Designed for the cell tissue venture company, Cellseed, this platform aims to streamline operations from cell collection to production and transport, enhancing the overall supply chain. Starting April 2026, HVCT RM will support Cellseed's clinical trials, specifically focusing on the commercialization of allogeneic cartilage cell sheets, tailored for treating knee osteoarthritis patients.

New Features for Enhanced Efficiency

The introduction of a novel function called "Resource Reservation Management" marks a pivotal upgrade in the capabilities of HVCT RM. This feature allows production companies to automate shipping schedules based on the availability of their manufacturing lines. Medical institutions can then easily select and reserve preferred dates from the available options, significantly simplifying the scheduling process. This automation not only saves time but also minimizes human errors, ensuring precise coordination and reduced workload for all stakeholders.

The Role of Cellseed in Regenerative Medicine

Cellseed is a bioventure at the forefront of regenerative medicine, particularly known for its unique technology of creating cell sheets from living cells. This method allows for the repair of tissues and organs that are difficult to heal with traditional drug therapies. The company has been working on translating this technology into practical applications, focusing on repairing damaged cartilage in the knees of osteoarthritis patients. Furthermore, Cellseed is engaged in projects for creating epithelial sheets to prevent strictures post-esophageal cancer surgeries and producing patient-specific cartilage regeneration sheets.

Ensuring Safe and Reliable Traceability

By implementing HVCT RM, the operational efficiency will significantly improve, facilitating a seamless transition to commercial production as manufacturing volumes increase. The integration of digital tools ensures that even during the earlier stages of clinical trials, processes are standardized, mitigating potential disruptions at the commercialization point. As responsibilities shift from clinical coordinators to manufacturing personnel, the simplified tasks will allow for a smoother transition in operations.

Future Developments

Hitachi is committed to addressing the most challenging issues in the industrialization of regenerative medicine. Plans are in place to enhance the HVCT RM's features through integration with surrounding systems such as Manufacturing Execution Systems (MES) and order management systems. The goal is to establish HVCT RM as the de facto standard platform for regenerative medicine products, thus contributing to broader industry challenges through multifaceted solutions that bridge IT and operational facilities.

Showcasing Innovations at INTERPHEX Japan

Hitachi will showcase its technologies and services related to pharmaceuticals and regenerative medicine at the upcoming INTERPHEX Japan event, taking place at Makuhari Messe from May 20-22, 2026. Visitors will have the opportunity to learn more about the HVCT RM platform and its impact on the future of medical advancements.

About Hitachi

Hitachi continues to leverage its strengths in IT and operational technologies to drive innovation across global infrastructure, reinforcing a balanced society that harmonizes environmental integrity, happiness, and economic growth. With significant investments in advanced technology and solutions like Lumada, the company aims to solve societal challenges and maximize lifetime value for its clients. For more information, visit Hitachi's official website.

About Cellseed

Founded on pioneering cell sheet engineering, Cellseed strives to bring innovative regenerative therapies to market. Their approach significantly enhances recovery options for patients by directly applying engineered cell sheets to damaged tissues or organs. With a strong focus on advancing clinical trials for cartilage regeneration and continuing their growth, Cellseed is committed to offering new treatment options to patients worldwide. For details, visit Cellseed's official website.